


Immune-Related Adverse Event: General Management Advice

Immune checkpoints are responsible for “switching off” the T-cell. Inhibition of these checkpoints allows for overexpression of the immune system. This immune system over-activation may result in side effects in healthy body tissues, which is how toxicities possible arise; however, the precise mechanism is unknown. These side effects are referred to as immune-related adverse events (irAEs). The overall incidence of grade 3 or 4 irAEs is higher with CTLA-4 blockers, compared to PD-1 and PDL-1 inhibitors, which are better tolerated. The combination of PD-1 inhibitor with a CTLA-4 inhibitor was associated more adverse reactions, especially grade 3 or 4 irAEs. However when managed correctly, promptly and with close monitoring, most irAEs are reversible



Interrupt SACT immunotherapy until discussed with Acute Oncology Team. Please contact on-call oncology/haematology team for advice. Ensure that Acute Oncology/Haematology team are informed of admission.